MedTrace Logo

Development and Validation of The Post-RT LARS Prediction Model (PORTLARS)

NCT05129215 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 901

Last updated 2022-11-30

No results posted yet for this study

Summary

Bowel dysfunction is common after a restorative rectal cancer resection. Neoadjuvant radiotherapy is an influential factor that impairs bowel function and quality of life. However, almost half patients who have received primary surgery with preoperative radiotherapy are able to restore a good or moderate bowel function in the long term. This multicenter observational study aims to identify the risk factors of severe bowel dysfunction after rectal cancer resection and neoadjuvant radiotherapy, in accordance with the LARS score, and to build a model that predicts long-term major LARS in the early stage of follow-up. Development and validation cohorts are enrolled from tertiary hospitals in China.

Conditions

Interventions

OTHER

Questionnaire

The LARS score is used for assessment of bowel dysfunction after rectal cancer resection.

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • Beijing Friendship Hospital

    collaborator OTHER

  • Sixth Affiliated Hospital, Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Qiyuan Qin, M.D. · Sixth Affiliated Hospital, Sun Yat-sen University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-06
Primary Completion
2022-10-31
Completion
2022-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05129215 on ClinicalTrials.gov